While the electric vehicle sector grabs the spotlight, it's the life sciences industry that's proving to be a lucrative powerhouse.
The lateral flow market is thriving, projected to hit a remarkable USD 11.21 billion this year.
Anteobind NTX stands out with its first-to-market advantage, offering unparalleled benefits and exceptional cost-efficiency.
It should be flying off the shelves.
The performance of the CMO requires serious reassessment to capitalize on this potential.
The mention of Vidcare hints at a possible major order in the pipeline, soon.
Anteobind NTX's impressive 365-day shelf life positions it as an industry game-changer, and it this needs to be shouted of the roof tops.
ADO needs to be aggressive.
https://www.anteotech.com/newsroom/anteobind-nxt-roundup/
(20min delay)